for personal use only - asx · 2011-03-11 · advanced molecular diagnostic systems 1 1 dalmore...

39
Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 97631287 F: +61 (0)3 97632817 www.generabiosystems.com FRIDAY 11 MARCH 2011 ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX:GBI) – Rights Issue Prospectus despatched Genera Biosystems Limited today despatched to eligible shareholders the Prospectus for its nonrenounceable rights issue to raise up to approximately $2.95 million. The Prospectus was lodged with ASIC and ASX on 28 February 2011. Personalised Entitlement and Acceptance Forms accompanied the despatched Prospectuses. A sample copy of the Prospectus and Entitlement and Acceptance Form is attached. The Offer closes at 5.00pm (AEDT) on 29 March 2011. For further information please contact Dr Allen Bollands Chief Executive Officer, Genera Biosystems Limited Telephone: 0423 943 600 Email: [email protected] About Genera Biosystems: Genera Biosystems Limited (ASX: GBI) is a molecular diagnostics company that develops, manufactures and distributes advanced molecular diagnostic tests. Its first product, PapType™, a test which simultaneously detects and genotypes human papillomavirus, is registered in Australia and the European Union. This notice does not constitute an offer to sell or the solicitation of an offer to buy, any securities in the United States. No action has been or will be taken to register, qualify or otherwise permit a public offering of the Rights or Rights Shares in any jurisdiction outside Australia or New Zealand. In particular, the Rights and Rights Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Rights may not be taken up by, and the Rights Shares may not be offered or sold to, persons in the United States, except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act and any applicable securities laws of any state or other jurisdiction of the United States. Note: The provision of this document is not, and should not be considered as, financial product advice. The information in this document is general information only, and does not take into account your individual objectives, taxation position, financial situation or needs. Before acting on the information, you should consider the appropriateness of the information, having regard to your objectives, taxation position, financial situation or needs. For personal use only

Upload: others

Post on 11-Jul-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

 Advanced Molecular Diagnostic Systems 

 

  1

1 Dalmore Drive, Scoresby, 

Victoria 3179 AUSTRALIA 

T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817 

www.generabiosystems.com  

FRIDAY 11 MARCH 2011 

ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX:GBI) – Rights Issue Prospectus 

despatched 

Genera Biosystems Limited today despatched to eligible shareholders the Prospectus for its non‐renounceable rights issue to raise up to approximately $2.95 million.  The Prospectus was lodged with ASIC and ASX on 28 February 2011.  Personalised Entitlement and Acceptance Forms accompanied the despatched Prospectuses.  A sample copy of the Prospectus and Entitlement and Acceptance Form is attached.  The Offer closes at 5.00pm (AEDT) on 29 March 2011.   

 For further information please contact 

Dr Allen Bollands Chief Executive Officer, Genera Biosystems Limited Telephone:  0423 943 600 E‐mail:  [email protected] 

 About Genera Biosystems:  Genera Biosystems Limited (ASX: GBI) is a molecular diagnostics company that develops, manufactures and distributes advanced molecular diagnostic tests. Its first product, PapType™, a test which simultaneously detects and genotypes human papillomavirus, is registered in Australia and the European Union.  This notice does not constitute an offer to sell or the solicitation of an offer to buy, any securities in the United States.  No action has been or will be taken to register, qualify or otherwise permit a public offering of the Rights or Rights Shares in any jurisdiction outside Australia or New Zealand.  In particular, the Rights and Rights Shares have not been, and will not be, registered under the US Securities Act of 1933 or the securities laws of any state or other jurisdiction of the United States.  Accordingly, the Rights may not be taken up by, and the Rights Shares may not be offered or sold to, persons in the United States, except in a transaction exempt from, or not subject to, the registration requirements of the US Securities Act and any applicable securities laws of any state or other jurisdiction of the United States.  Note: The provision of this document is not, and should not be considered as, financial product advice. The information in this document is general information only, and does not take into account your individual objectives, taxation position, financial situation or needs. Before acting on the information, you should consider the appropriateness of the information, having regard to your objectives, taxation position, financial situation or needs. 

For

per

sona

l use

onl

y

Page 2: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

� � Advanced�Molecular�Diagnostic�Systems�

ACN 098 663 837

PROSPECTUS

Subject to the terms of the Offer, a non renounceable rights issue offer of

one (1) Rights Share for every seven (7) Shares held at the Record Date at an Offer Price

of $0.33 per Rights Share to raise up to approximately $2.95 million, with one (1) bonus

attaching New Option (exercisable at $0.33 per New Option to expire on 8 April 2013)

for every Rights Share purchased.

The�Offer�closes�at�5.00pm�(AEDT)�on�29�March�2011�

IMPORTANT INFORMATION

This document is important and requires your immediate attention. Applicants

should read this Prospectus in its entirety before deciding whether to apply for

the Rights Shares and New Options. If after reading this Prospectus you have

any questions about the Rights Shares or New Options being offered pursuant to

this Prospectus or any other matter, then you should consult your professional

adviser.

An� investment� in�the�Rights�Shares�and�New�Options�offered�by�this�Prospectus�should�be�considered�speculative.�

1

For

per

sona

l use

onl

y

Page 3: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

TABLE�OF�CONTENTS�

IMPORTANT�NOTICE ...........................................................................................................................3

THE�AIM�OF�THE�OFFER.......................................................................................................................5

KEY�DETAILS........................................................................................................................................6

KEY�DATES ..........................................................................................................................................6

LETTER�FROM�THE�CHAIRMAN ............................................................................................................7

1. ........................................................................................................................8OFFER�SUMMARY

2. ...........................................................................15OVERVIEW�OF�GENERA�BIOSYSTEMS�LIMITED

3 ............................................................................................................................17RISK�FACTORS

4. ........................................................................20ACTION�REQUIRED�BY�ELIGIBLE�SHAREHOLDERS

5. ..................................................................................23ADDITIONAL�STATUTORY�INFORMATION

6. .........................................................................................................25FINANCIAL�INFORMATION

7. ...................................................................................................27REPORTING�AND�DISCLOSURE

8. ......................................................................................................29ADDITIONAL�INFORMATION

9. ...........................................................................................................32DIRECTORS’�STATEMENT

10. ..............................................................................................................................33DEFINITIONS

11. ............................................................................................................36CORPORATE�DIRECTORY

2

For

per

sona

l use

onl

y

Page 4: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

IMPORTANT�NOTICE�

This� Prospectus� is� dated� 28� February� 2011� and� is� issued� pursuant� to� section� 713� of� the� Corporations� Act.� � A� copy� of� this�Prospectus�was�lodged�with�ASIC�on�the�same�date.��Neither�ASIC�nor�the�ASX�takes�any�responsibility�for�the�contents�of�this�Prospectus.� The� Expiry�Date� of� this� Prospectus� is� the� date�which� is� 13�months� after� the� date� of� this� Prospectus.� �No�New�Securities�will�be�allotted�or�issued�on�the�basis�of�this�Prospectus�later�than�the�Expiry�Date.�

Genera�Biosystems�Limited�will�not�accept�Applications�for�New�Securities�under�this�Prospectus�until�8�March�2011.�

This�Prospectus�does�not�constitute�an�offer� in�any�place�where,�or�to�any�person�to�whom,�it�would�not�be�lawful�to�make�such�an�offer.��The�Offer�of�New�Securities�under�this�Prospectus�is�made�to�Australia�and�New�Zealand�investors�only.��The�distribution�of� this�Prospectus� in� jurisdictions�outside�the�Commonwealth�of�Australia�or�New�Zealand�may�be�restricted�by�law�and�persons�who�come�into�possession�of�it�should�seek�advice�on�and�observe�any�such�restrictions.�Any�failure�to�comply�with�such�restrictions�may�constitute�a�violation�of�applicable�securities�law.�

The� fact� that�ASX�may�grant�Official�Quotation�of� the�Rights� Shares� should�not�be� taken� in� anyway�as� an� indication�of� the�merits�of�the�Company�or�the�Rights�Shares�and�bonus�attaching�New�Options�(together�New�Securities).�

The�Company�will�apply�for�Official�Quotation�of�the�Rights�Shares�offered�under�this�Prospectus�within�7�days�of�the�date�of�this�Prospectus.�In�the�event�of�exercise�of�a�New�Option�the�Company�will�apply�for�Official�Quotation�of�the�Shares�within�three�(3)�Business�Days�of�the�date�of�issue�of�the�Shares.�

The�Company�is�admitted�to�the�Official�List�of�ASX�and�its�Shares�are�continuously�quoted�securities�in�the�terms�of�section�713�of�the�Corporations�Act.�

This�Prospectus�provides�information�for�Eligible�Shareholders�to�decide�if�they�wish�to�take�up�their�Entitlement�and�apply�for�Top�Up�Shares�and�should�be� read� in� its�entirety.� If,�after� reading� this�Prospectus,�you�have�any�questions�about� the�Offer�please�contact�your�stockbroker,�accountant�or�other�professional�adviser.�

If� you� are� entitled� as� an� Eligible� Shareholder� to� apply� for� Rights� Shares� and� New� Options� pursuant� to� the� Offer,� your�personalised�Entitlement�and�Acceptance�Form�accompanying�this�Prospectus�shows�the�number�of�Rights�Shares�and�New�Options�for�which�you�are�entitled�to�apply.��In�addition,�you�can�also�apply�for�Top�Up�Shares�in�the�manner�described�in�this�Prospectus�by�indicating�how�many�additional�Shares�you�wish�to�subscribe�for�in�the�Entitlement�and�Acceptance�Form.��

Applications�for�New�Securities�cannot�be�accepted�until�7�days�after�the�lodgement�of�this�Prospectus�with�ASIC.��ASIC�may�extend�this�7�day�period�by�a�further�period�of�up�to�7�days.�Applications�for�Rights�Shares�and�New�Options�under�the�Offer�may�only�be�made�by�forwarding�a�complete�personalised�Entitlement�and�Acceptance�Form�to�the�Company,�or�by�BPAY®�in�accordance�with�the�directions�on�your�Entitlement�and�Acceptance�Form.��As�the�Offer�is�non�renounceable,�Shareholders�do�not� have� the� right� to� sell� their� Entitlements.� Shareholders� have� the� opportunity� to� subscribe� for� all,� part� or� none� of� their�Entitlement�to�Rights�Shares�and�New�Options�under�the�Offer,�and�to�apply�for�Top�Up�Shares.�

It�is�important�that�Shareholders�intending�to�accept�their�Entitlement�(or�part�thereof)�take�action�as�described�in�section�4�of�this�Prospectus.��This�section�also�sets�out�how�Shareholders�may�apply�for�Top�Up�Shares�in�addition�to�their�Entitlement.�

Defined�terms�and�abbreviations�used�in�the�Prospectus�are�explained�in�the�Definitions�section�(section�10).�All�financial�amounts�shown�in�this�Prospectus�are�expressed�in�Australian�dollars�unless�otherwise�stated.�

THIS�DOCUMENT�IS�IMPORTANT�AND�SHOULD�BE�READ�IN�ITS�ENTIRETY.��AN�INVESTMENT�IN�GENERA�BIOSYSTEMS�LIMITED�SHOULD�BE�CONSIDERED�SPECULATIVE.�

®Registered�to�BPAY�Pty�Limited�ABN�69�079�137�518�

3

For

per

sona

l use

onl

y

Page 5: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

New�Zealand�investor�warning�statement�

The�following�disclosure�is�provided�under�regulation�13�Securities�(Mutual�Recognition�of�Securities�Offerings���Australia)�Regulations�2008�(NZ).�

General�

(a)�����This�Offer�to�New�Zealand�investors�is�a�regulated�offer�made�under�Australian�and�New�Zealand�law.��In�Australia,�this�is�Chapter�8�of�the�Corporations�Act�2001�and�Regulations.��In�New�Zealand�this�is�Part�5�of�the�Securities�Act�1978�and�the�Securities�(Mutual�Recognition�of�Securities�Offerings�–�Australia)�Regulations�2008.�

(b)�����This�Offer�and�the�content�of�the�offer�document�are�principally�governed�by�Australian�rather�than�New�Zealand�law.��In�the�main,�the�Corporations�Act�2001�and�Regulations�(Australia)�set�out�how�the�offer�must�be�made.�

(c)������There�are�differences�in�how�securities�are�regulated�under�Australian�law.��For�example,�the�disclosure�of�fees�for�collective�investment�schemes�is�different�under�the�Australian�regime.�

(d)�����The�rights,�remedies�and�compensation�arrangements�available�to�New�Zealand�investors�in�Australian�securities�may�differ�from�the�rights,�remedies�and�compensation�arrangements�for�New�Zealand�securities.�

(e)�����Both�the�Australian�and�New�Zealand�securities�regulators�have�enforcement�responsibilities�in�relation�to�this�Offer.��If�you�need�to�make�a�complaint�about�this�offer,�please�contact�the�Securities�Commission,�Wellington,�New�Zealand.��The�Australian�and�New�Zealand�regulators�will�work�together�to�settle�your�complaint.�

(f)������The�taxation�treatment�of�Australian�securities�is�not�the�same�as�for�New�Zealand�securities.�

(g)�����If�you�are�uncertain�about�whether�this�investment�is�appropriate�for�you,�you�should�seek�the�advice�of�an�appropriately�qualified�financial�adviser.�

Offer�not�in�NZ�dollars�

(a)�����The�Offer�may�involve�a�currency�exchange�risk.��The�currency�for�the�securities�is�not�New�Zealand�dollars.��The�value�of�the�securities�will�go�up�or�down�according�to�the�changes�in�the�exchange�rate�between�that�currency�and�New�Zealand�dollars.��These�changes�may�be�significant.�

(b)�����If�you�expect�the�securities�to�pay�any�amounts�in�a�currency�that�is�not�New�Zealand�dollars,�you�may�incur�significant�fees�in�having�the�funds�credited�to�a�bank�account�in�New�Zealand�in�New�Zealand�dollars.�

Traded�on�a�financial�market�

If�the�securities�are�able�to�be�traded�on�a�securities�market�and�you�wish�to�trade�the�securities�through�that�market,�you�will�have�to�make�arrangements�for�a�participant�in�that�market�to�sell�the�securities�on�your�behalf.��If�the�securities�market�does�not�operate�in�New�Zealand,�the�way�in�which�the�market�operates,�the�regulation�of�participants�in�that�market,�and�the�information�available�to�you�about�the�securities�and�trading�may�differ�from�securities�markets�that�operate�in�New�Zealand.�

4

For

per

sona

l use

onl

y

Page 6: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

THE�AIM�OF�THE�OFFER�

The�aim�of�the�Offer�is�to�raise�sufficient�funds�to�allow�the�Company�to�continue�pursuing�its�principal�commercialisation� strategy� –� that� is,� the� development� of� a� modified� HPV� test,� based� upon� its�proprietary�AmpaSand�bead� technology,� for�a� top�10�global�diagnostic�company�partner.� In�addition,�the� Company� will� pursue� other� strategies� aimed� at� enhancing� the� attractiveness� of� its� tests� and�technology,�and�identifying�other�commercial�partners.�Finally,�it�will�continue�with�the�development�of�its�multiplexed�respiratory�pathogen�test.�

Funds�raised�through�this�Offer�will�be�applied�as�follows:�

� �R&D� $220,000� �

� Clinical�Trials� $500,000�

� Instrument�Development� $500,000�

� Manufacturing� $340,000�

� IP�prosecution�costs� $335,000�

� Other�working�capital� $1,055,000�

Total� $2,950,000�

If�less�than�the�maximum�amount�is�received,�Genera�will�pursue�other�options�available�to�it�as�a�listed�company.�

Funds�are�to�be�raised�by�offering�all�Eligible�Shareholders�recorded�on�the�Company’s�share�register,�as�at�7.00�pm� (AEDT),� 8�March�2011� (Record�Date)� the�opportunity� to�acquire�one� (1)�Rights� Share� for�every� seven� (7)� Shares� they� hold.� � For� every� Rights� Share� subscribed� for� and� issued,� Eligible�Shareholders�will�be� issued�a�bonus�New�Option�at�no�cost,�but�with�an�Exercise�Price�of�$0.33�each.��The�terms�of�the�New�Options�are�set�out�in�section�5.1.���

Eligible�Shareholders�may�apply�also�for�additional�Shares�(Top�Up�Shares)�in�excess�of�their�Entitlement�under�the�Top�Up�Facility,�though�there�is�no�guarantee�they�will�receive�the�number�of�Top�Up�Shares�applied�for.���

Shares�issued�upon�exercise�of�the�New�Options�will�be�quoted�on�ASX�and�consequently�will�be�able�to�be�traded�on�market.��The�New�Options�will�not�be�quoted�on�ASX.�

5

For

per

sona

l use

onl

y

Page 7: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

KEY�DETAILS�

Rights�Shares�

Offer�Price� $0.33�per�Share�

Entitlement� 1�Rights�Share�for�every�7�Shares�held�

Maximum�no.�of�Rights�Shares�offered�under�this�Prospectus�

8,952,897�(approximately)�

Maximum�amount�to�be�raised�(before�Offer�Costs)�

Shares�on�issue�following�the�Offer�(if�the�Offer�is�fully�subscribed)�

$2,950,000�(approximately)�

71,623,176�(approximately)�

New�Options�

New�Option�price� Nil�immediately�–�the�Exercise�Price�will�apply�if�exercised��

Exercise�Price� $0.33�per�New�Option�

Expiry�Date� 5.00pm�(AEST)�8�April�2013�

Entitlement� 1�New�Option�for�every�Rights�Share�subscribed�for�

Maximum�no.�of�New�Options�offered�under�this�Prospectus� 8,952,897�(approximately)�

Amount�to�be�raised�(before�Offer�Costs)� Nil�immediately����Up�to�approximately�$2,950,000�if�all�New�Options�are�exercised�before�the�Expiry�Date��

KEY�DATES�

Announcement�of�Offer�� 23�February�2011�

Lodgement�of�Prospectus�with�ASIC�and�ASX� 28�February�2011�

Record�Date�for�determining�Entitlements� 8�March�2011�7.00pm�(AEDT)��

Despatch�of�Prospectus� 15�March�2011�

Opening�Date� 15�March�2011�

Closing�Date� 29�March�2011��5.00pm�(AEDT)��

Rights�Shares�quoted�on�a�deferred�settlement�basis� 30�March�2011�

Notification�given�to�ASX�of�under�subscriptions� 1�April�2011�

6

For

per

sona

l use

onl

y

Page 8: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

LETTER�FROM�THE�CHAIRMAN�

Dear�Shareholder�

As�announced�to�ASX�on�23�February�2011,�the�Company�proposes�to�raise�approximately�$2.95�million�by�way�of�a�non�renounceable�rights�issue�of�one�(1)�Rights�Share�for�every�seven�(7)�Shares�held.��In�addition,�for�every�Rights�Share�purchased,�Shareholders�will�be�issued�one�(1)�bonus�New�Option�at�no�cost,�but�exercisable�at�$0.33�each.�

The�Closing�Date�for�acceptances�and�payment�is�5.00pm�(AEDT)�on�29�March�2011.�

The�purpose�of�this�capital�raising�is�to�enable�Genera�Biosystems�Limited�(Genera)�to�continue�pursuing�its�principal� commercialisation� strategy� –� that� is,� the� development� of� a� modified� HPV� test,� based� upon� its�proprietary�AmpaSand�bead� technology,� for� a� top� 10� global� diagnostic� company�partner.� In� addition,� the�Company�will�pursue�other�strategies�aimed�at�enhancing�the�attractiveness�of�its�tests�and�technology,�and�identifying� other� commercial� partners.� Finally,� it� will� continue� with� the� development� of� its� multiplexed�respiratory�pathogen�test.�

Please� read� the�Prospectus� carefully� and� consult� your� financial� advisor,� accountant�or� stockbroker�before�deciding�whether�or�not�to�subscribe�under�the�Offer.�

This�Prospectus�contains�information�about�Genera’s�operations,�financial�position�and�future�plans.�It�also�outlines�potential�risks�associated�with�this�investment.�We�encourage�you�to�read�this�document�carefully�before�making�your�investment�decision.�

We�believe�our�strategic�pathway�to�commercialisation�is�realistic�and�achievable,�having�regard�to�the�particular�circumstances�of�the�Company.��Your�Board�is�enthusiastic�about�the�future�of�Genera�and�we�commend�the�Offer�for�your�consideration.�

If�you�wish�to�subscribe�for�New�Securities,�please�complete�and�return�the�accompanying�Entitlement�and�Acceptance� Form� to� Computershare� Investor� Services� Pty� Limited,� together� with� a� cheque� or� bank� draft�made�payable�to�“Genera�Biosystems�Rights�Issue�Account”�and�crossed�‘Not�Negotiable’.��Alternatively�you�can�pay�your�Application�Monies�via�BPAY�by�following�the�instructions�on�the�Entitlement�and�Acceptance�Form.�

We�look�forward�to�the�continued�growth�and�success�of�the�Company.�

Yours�sincerely�

Fernando�Careri�

Chairman�

7

For

per

sona

l use

onl

y

Page 9: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

1 OFFER�SUMMARY�

This� summary� is� not� intended� to� provide� full� details� of� the� Offer.� � Shareholders� should� read� this�Prospectus�in�full�to�make�a�fully�informed�investment�decision.��Details�of�recent�announcements�are�set�out�at�section�7.2.�

1.1 Overview�of�the�Offer�

In�summary:��

� The�Offer�is�an�opportunity�to�acquire�Rights�Shares�at�$0.33�each;�

� For�every�Rights�Share�purchased,�Shareholders�will�be�issued�one�(1)�bonus�New�Option�at�no�cost;�

� Proceeds� from� the� Offer� will� be� used� primarily� to� continue� pursuing� its� principal�commercialisation�strategy�–�that� is,� the�development�of�a�modified�HPV�test,�based�upon�its�proprietary� AmpaSand� bead� technology,� for� a� top� 10� global� diagnostic� company� partner.� In�addition,�the�Company�will�pursue�other�strategies�aimed�at�enhancing�the�attractiveness�of�its�tests�and�technology,�and� identifying�other�commercial�partners.�Finally,� it�will� continue�with�the�development�of�its�multiplexed�respiratory�pathogen�test;�

� No�Brokerage�or�stamp�duty�will�be�payable�on�the�issue�of�the�Rights�Shares�or�New�Options;�

� Any�Shortfall�following�the�issue�of�the�Rights�Shares�and�Top�Up�Shares�will�be�placed�at�the�discretion�of�the�Directors.��

The�above�should�be�read�subject� to� the�more�detailed� information� in� this�Prospectus.� � In�particular,�some�of�the�key�risk�factors�of�an�investment�in�Genera�are�detailed�in�section�3.��These�include:�

� future�capital�requirements�

� technology�

� retaining�and�attracting�key�personnel��

� general�market�risks.�

8

For

per

sona

l use

onl

y

Page 10: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

1.2 Effect�on�capital�structure�

The�effect�of�the�Offer�on�the�capital�structure�of�the�Company,�assuming�that�all�New�Securities�are�issued�in�accordance�with�the�Offer,�is�as�follows:�

Shares�on�issue�at�31�December�2010� 62,670,279�

Options�on�issue�at�31�December�2010� 4,044,325�

Shares�on�issue�at�the�date�of�this�Prospectus� 62,670,279�

Options�on�issue�at�the�date�of�this�Prospectus� 4,044,325�

Rights�Shares�to�be�issued�under�the�Offer�(approximately)1� 8,952,897�

New�Options�to�be�issued�under�the�Offer�(approximately)1� 8,952,897�

Total�number2�of�Shares�on�issue�after�issue�of�Rights�Shares� 71,623,176�

Total�number2�of�Options�on�issue�after�issue�of�Rights�Shares�

12,997,222�

Amount�to�be�raised�from�the�issue�of�Rights�Shares�under�the�Offer�(before�Offer�Costs)�

� $2.95�million�� (approximately)�

Market�capitalisation�of�total�number�of�Shares�on�issue�after�issue�of�Rights�Shares,�at�the�Offer�Price3�

� $23.64�million�� (approximately)�

1�� Subject�to�possible�minor�rounding�adjustments�

2� Assumes�no�existing�Options�are�exercised�prior�to�the�Record�Date�

3� This�assumes�the�Offer�Price�of�$0.33.��There�is�no�guarantee�as�to�the�Company’s�market�

capitalisation�following�the�Offer�and�issue��of�the�Rights�Shares�and�quotation�on�ASX�or�in�the�future.�

1.3�������Important�dates:�

Announcement�of�Offer�� 23�February�2011�

Application�for�Official�Quotation�(Appendix�3B)� 28�February�2011�

Lodgement�of�Prospectus�with�ASIC�and�ASX� 28�February�2011�

9

For

per

sona

l use

onl

y

Page 11: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

Record�Date�for�determining�Entitlements� 8�March�2011�at�7.00pm�(AEDT)��

Despatch�of�Prospectus� 15�March�2011�

Opening�Date� 15�March�2011�

Closing�Date� 29�March�2011�at�5.00pm�(AEDT)��

Rights�Shares�quoted�on�a�deferred�settlement�basis� 30�March�2011�

Notification�given�to�ASX�of�under�subscriptions� 1�April�2011�

Allotment�of�Rights�Shares�and�Issue�of�New�Options� 5�April�2011�

Despatch�of�Holding�Statements� 6�April�2011�

Anticipated�date�of�Official�Quotation�of�Rights�Shares� 7�April�2011�

Expiry�Date�(at�which�time�New�Options�expire)� 8�April�2013�

�These�dates�are�indicative�only.�Genera�Biosystems�Limited�reserves�the�right,�subject�to�the�Corporations�Act�and�Listing�Rules,� to�vary�the�dates�and�times�of�the�Offer,�without�prior�notice,� including�closing�the�Offer�before�the�scheduled�Closing�Date.�

The�Offer�of�New�Securities�is�restricted�to�Eligible�Shareholders�who�are�registered�as�Shareholders�at�the�Record�Date.�Eligible�Shareholders�must�be�recorded�in�the�Company’s�share�register�as�having�an�address� in� Australia� or� New� Zealand.� The� number� of� Rights� Shares� and� New� Options� which�Shareholders�are�entitled�to�subscribe�for�are�shown�on�the�accompanying�Entitlement�and�Acceptance�Form.���

Eligible�Shareholders�may�apply�also�for�additional�Shares�(Top�Up�Shares)�in�excess�of�their�Entitlement�under�the�Top�Up�Facility,�though�there�is�no�guarantee�they�will�receive�the�amount�applied�for,�if�any,�Top�Up�Shares.���

Applications�for�New�Securities�under�the�Offer�can�only�be�made�by�completing�the�Entitlement�and�Acceptance�Form�in�full,�in�accordance�with�the�instructions�on�it,�and�returning�it�to�the�Company�as�directed.�

Fractional�entitlements�will�be�rounded�up�to�the�nearest�whole�number�of�Rights�Shares.�

The�Directors� reserve� the� right� to� accept,� scale�back�or� refuse� any� application� for� additional� Top�Up�Shares� in� excess� of� a� Shareholder’s� Entitlement.� � Genera� will� refund� any� amount� not� used� for� the�additional�Top�Up�Shares�applied�for.��

The�Offer�is�scheduled�to�close�at�5.00pm�(AEDT)�on�29�March�2011.��To�participate,�Entitlement�and�Acceptance�Forms�must�be�received�by�that�time�by�the�Company,�together�with�a�cheque�or�bank�draft�in�Australian�currency�drawn�on�an�Australian�branch�of�a�financial�institution�for�the�amount�of�the�Application.��Alternatively,�Applicants�can�pay�by�BPAY�in�line�with�the�instructions�set�out�in�the�Entitlement�and�Acceptance�Form�and�in�this�Prospectus,�before�this�time�and�date.�

10

For

per

sona

l use

onl

y

Page 12: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

1.4 �Description�of�the�Offer�

Eligible� Shareholders� can�apply� for�Rights� Shares�and� receive,�with�each�Rights� Share� subscribed� for,�one� bonus� attaching�New�Option� at� no� cost,� but� exercisable� before� the� Expiry� Date� for� $0.33� each.��Eligible�Shareholders�may�also�apply�for�additional�Shares�under�the�Top�Up�Facility.�

Up�to�approximately�$2.95�million�will�be�raised�under�the�Offer�(before�Offer�Costs).���

Rights�Shares�

The� Company� is� offering� approximately� 8,952,897� Rights� Shares� to� Shareholders�who� are� registered�Shareholders�at�the�Record�Date�(Eligible�Shareholders).�

The�Rights�Shares�are�being�offered�on�the�basis�of�one�(1)�Rights�Share�for�every�seven�(7)�Shares�held�at�the�Record�Date�at�an�Offer�Price�of�$0.33�per�Rights�Share,�with�one�(1)�bonus�attaching�New�Option�(exercisable�at�$0.33�each�on�or�before�8�April�2013).�

The� number� of� Rights� Shares� to� which� you� are� entitled� as� an� Eligible� Shareholder� is� shown� on� the�accompanying�Entitlement�and�Acceptance�Form.���

By�example,�if�an�Eligible�Shareholder�owns�70,000�Shares,�the�Eligible�Shareholder�will�be�entitled�to�apply�for�10,000�Rights�Shares�and�receive�10,000�New�Options�under�this�Offer.�

Top�Up�Shares��

If�you�have�applied�to�take�up�all�of�your�Entitlement�to�Rights�Shares,�you�may�also�apply�for�Top�Up�Shares�by�completing�the�relevant�section�on�the�Entitlement�and�Acceptance�Form.�

There�is�no�cap�on�the�number�of�additional�Shares�Eligible�Shareholders�may�apply�for,�although�the�Top�Up�Share�pool�will�be�limited�to�the�amount�of�Shortfall�available�under�the�Offer,�so�scaling�may�apply.��

There�is�no�guarantee�that�any�Top�Up�Shares�applied�for�will�be�issued�to�you.�

Shortfall�

Any�Entitlement�to�Rights�Shares�which�are�not�applied�for�by�Eligible�Shareholders,�including�under�the�Top� Up� Facility� by� the� Closing� Date� will� become� ‘Shortfall’.� � In� accordance� with� Listing� Rule� 7.2�Exception� 3,� the� Directors� expressly� reserve� their� right� to� issue� Shortfall� Shares� at� their� discretion�within�3�months�of�the�Closing�Date.�

1.5 .��������Calculating�Entitlements�and�Application�Monies�

For�the�purposes�of�the�Offer,�any�fraction�of�an�Entitlement�will�be�rounded�up.��For�example,�if�a�Shareholder�holds�141�Shares�on�the�Record�Date,�their�full�Entitlement�will�be�21�Rights�Shares�(plus�21�bonus�attaching�New�Options).�

Any�additional�Application�Monies�received�for�more�than�your�final�allocation�of�Rights�Shares,�and�if�applicable,�any�additional�Top�Up�Shares,�will�not�be�refunded�to�the�Applicant�if�this�amount�is�less�than�$1.00.�

11

For

per

sona

l use

onl

y

Page 13: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

1.6 ��������Closing�Date�

The�Prospectus,�accompanied�by�the�Entitlement�and�Acceptance�Forms,�will�be�despatched�by�no�later�than�15�March�2011.�

The�Offer�will�close�at�5.00pm�(AEDT)�on�29�March�2011,�subject�to�the�right�of�Directors�to�extend�the�Closing�Date.�

As�the�Offer�is�non�renounceable,�Eligible�Shareholders�do�not�have�the�right�to�sell�their�Entitlements.�Eligible�Shareholders�have�the�opportunity�to�subscribe�for�all,�part�or�none�of�their�Entitlement.�

To�the�extent�that�any�part�or�all�of�an�Entitlement�is�not�taken�up,�it�will�lapse�on�the�Closing�Date.�

Eligible� Shareholders� should�be�aware� that� their� Entitlement�may�have�value.� If� you�decide�not� to�accept�all�or�part�of�your�Entitlement,�your�Entitlement�will�lapse.�It�is�therefore�important�that�you�take� action� if� you� wish� to� accept� your� Entitlement� in� accordance� with� the� instructions� on� the�accompanying�Entitlement�and�Acceptance�Form.�Action�required�by�Eligible�Shareholders�is�set�out�is�section�4.�

1.7 ���������What�will�happen�if�I�accept�my�full�Entitlement?�

If� you� take�up�your� full� Entitlement,� your�pro� rata� shareholding� in�Genera�will� not�be�diluted�by� the�issue�of�Rights�Shares�and�any�exercise�of�New�Options.�

If�you�apply�for�and�are�issued�additional�Shares�under�the�Top�Up�Facility,�your�proportionate�interest�in�Genera�will�increase�correspondingly.���

1.8 ���������What�will�happen�if�I�do�not�accept�my�full�Entitlement?�

If� you� do� not� take� up� your� full� Entitlement� under� the� Offer,� to� the� extent� holders� of� New� Options�exercise� their�Options�and�acquire� Shares,� and� to� the�extent�Eligible� Shareholders�acquire�additional�Shares� under� the� Top� Up� Facility,� then� your� shareholding� in� Genera� will� be� diluted� as� will� your�corresponding�rights�to�future�dividends�of�Genera�(if�any).�

As�the�Offer� is�non�renounceable,� if�you�decide�not�to�take�up�all�of�your�Entitlement,� it�will� lapse�on�the�Closing�Date�to�the�extent�that�it�is�not�taken�up.�

Any�Shortfall,�not�otherwise�subscribed� for�under� the�Top�Up�Facility,�will�be� issued�at� the�Directors’�discretion�within�3�months�of�the�Closing�Date.�

1.9 ���������Brokerage�and�stamp�duty�

No�brokerage�or� stamp�duty� is�payable�by� the�Applicant� in� relation� to� the�Offer.� �However,�you�may�have�to�pay�brokerage�on�any�subsequent�trading�of�your�New�Options�or�Rights�Shares�on�ASX�after�they�have�been�quoted�on�ASX.�

12

For

per

sona

l use

onl

y

Page 14: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

1.10 ��Shareholders�outside�Australia�or�New�Zealand�

The�Company�will�only�extend�the�Offer�to�Eligible�Shareholders�with�registered�addresses�in�Australia�or� New� Zealand.� � In� accordance� with� Listing� Rule� 7.7� and� section� 9� of� the� Corporations� Act,� the�Company� considers� it� would� be� unreasonable� to� extend� the� Offer� to� Shareholders� with� registered�addresses� in� other� jurisdictions� having� regard� to� the� small� number� of� such� Shareholders,� the� small�number� and� value� of� New� Securities� that� would� be� offered� in� such� jurisdictions� and� the� costs� of�complying�with�legal�and�regulatory�requirements�in�those�jurisdictions.�

This�Prospectus�does�not�constitute�an�offer�in�any�place�in�which,�or�to�any�person�to�whom,�it�would�not�be�lawful�to�make�such�an�offer.�

1.11 ��Terms�of�New�Options�and�ranking�of�Shares�

The�New�Options�are�subject�to�the�terms�and�conditions�described�in�this�Prospectus.��For�each�New�Option�exercised�by�paying�the�Exercise�Price�of�$0.33�to�the�Company�on�or�before�8�April�2013,�the�option�holder�will�be�issued�one�(1)�Share.��Shares�acquired�upon�the�exercise�of�the�New�Options�will�be�fully�paid�and�rank�equally�with�Shares�already�issued.� �The�Company�will�make�application�to�ASX�for�the�Shares�to�be�quoted.�

1.12 ��Allotment�and�Application�Money�on�Trust�

New�Options�and�Rights�Shares�are�expected�to�be�allotted�on�5�April�2011�and�holding�statements�will�be� dispatched� no� later� than� 6� April� 2011� at� the� address� appearing� in� the� Company’s� share� register,�subject�to�any�changes�to�the�Offer�timetable.�All�Application�Monies�received�before�the�New�Options�and�Rights�Shares�are�issued�will�be�held��on�trust�pending�allotment.��The�Company�will�be�entitled�to�all�interest�paid�or�accrued�on�Application�Monies.��After�the�Rights�Shares�and�New�Options�are�issued�to�successful�Applicants,�the�Application�Monies�held�on�trust�will�be�payable�to�Genera.�

1.13 ASX�Quotation�

Application�will� be�made�within� seven� (7)� days�of� the�date�of� issue�of� this�Prospectus� for� the�Rights�Shares� to�be�granted�Official�Quotation�by�ASX.� If� such�application� is�not�made�within� this�period,�or�Official�Quotation�of� the�Rights� Shares� is�not� granted�by�ASX�within� three� (3)�months�of� the�date�of�issue�of�this�Prospectus,�then�all�Application�Monies�received�pursuant�to�this�Prospectus�will�be�repaid�as� soon� as� practicable,� without� any� interest� accrued� on� Application�Monies� held� in� the� application�account.���

The�fact�that�ASX�may�agree�to�grant�Official�Quotation�of�the�Rights�Shares�should�not�be�taken�in�any�way�as�an�indication�of�the�merits�of�the�Company�or�its�Rights�Shares.��ASX�takes�no�responsibility�for�the�contents�of�this�Prospectus.�

1.14 CHESS�

The� Company� will� apply� to� have� the� Rights� Shares� and� New� Options� issued� under� this� Prospectus�admitted�to�participate� in�CHESS�in�accordance�with�the�Listing�Rules�and�the�ASTC�Settlement�Rules.��Under�CHESS,�Eligible�Shareholders�will�not�receive�a�certificate�but�will�receive�a�holding�statement�for�Rights�Shares�and�New�Options�.�

13

For

per

sona

l use

onl

y

Page 15: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

1.15 Market�price�of�Genera’s�Shares�on�ASX�

The� Company� is� a� disclosing� entity� for� the� purposes� of� the� Corporations� Act� and� its� Shares� are�enhanced�disclosure�securities�quoted�on�ASX.��The�highest�and�lowest�closing�sale�prices�for�Shares�on�ASX�during�the�3�months�immediately�preceding�the�date�of�this�Prospectus,�were�$0.53�and�$0.38�per�Share.�The�closing�price�for�Shares�on�ASX�on�25�February�2011�was�$0.39�per�Share.�

1.16 Half�Year�Report�and�quarterly�cash�flow�report�

A�summary�of�the�strategic�focus,�major�activities�and�financial�information�relating�to�the�Company�is�contained�in�the�Half�Year�Report�for�the�year�ended�31�December�2010.��A�full�copy�of�the�Half�Year�Report�has�been�lodged�with�ASX�and�is�also�available�on�the�Company’s�website.��The�Half�Year�Report,�in�conjunction�with�the�Appendix�4D,�was�lodged�with�ASX�on�24�February�2011.�

The�Company’s�quarterly�Appendix�4C�cash�flow�report�for�the�quarter�ended�31�December�2010�was�lodged�with�ASX�on�31�January�2011.��

Any�person�who�wishes�to�obtain�a�free�copy�of�the�Annual�Report,�Half�Year�Report�or�any�continuous�disclosure�notices�by�Genera,�as�referenced�in�section�7.2,�may�request�copies�from�the�Company.�

1.17 ���Summary�only�

This�summary�is�not�intended�to�provide�full�details�of�the�investment�opportunity.�Shareholders�should�read�this�Prospectus�in�full�to�make�a�fully�informed�investment�decision.��

The� Directors� do� not� consider� it� appropriate� to� give� Shareholders� advice� regarding� the� taxation�consequences� of� the� Offer.� � Neither� the� Company� nor� any� of� its� officers� accepts� any� liability� or�responsibility�arising� from� this�Offer.� � Shareholders� should� therefore�consult� their�own� tax�adviser� in�connection�with�the�taxation�implications�of�the�Offer.�

1.18 ���Enquiries�

If� you� require� advice� as� to�whether� to� accept� your� Entitlement,� you� should� seek�professional� advice�from�your�legal,�investment�or�other�adviser.�

14

For

per

sona

l use

onl

y

Page 16: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

2 OVERVIEW�OF�GENERA�BIOSYSTEMS�LIMITED�

2.1�� Company�overview�

Genera�Biosystems�develops�and�manufactures�molecular�diagnostic�tests,�for�the�global�commercial�pathology�market.��PapTypeTM,�Genera’s�first�test,�is�based�upon�the�Company’s�proprietary�bead�based�DNA�detection�technology.��It�is�used�to�detect�and�differentiate�the�human�papillomavirus�viruses�(HPV)�responsible�for�causing�cervical�cancer.��PapType�is�listed�on�the�Australian�Register�of�Therapeutic�Goods�and�is�CE�IVD�marked�(i.e.�approved�for�use�in�Europe).��Other�tests,�based�upon�the�same�technology�are�currently�in�development.�

The�Company�is�based�in�Scoresby�in�Victoria,�and�is�listed�on�ASX�under�the�ticker�symbol�GBI.�

HIGHLIGHTS��

Commercial�

May�2010:�Genera�signed�an�R&D�agreement�with�a�global�top�10�diagnostics�industry�partner,�with�a�view�to�the�global�commercialisation�of�the�PapType�test.��The�objective�of�the�R&D�was�to� undertake� some� subtle� redesigns� of� the� original� PapType� in� order� to� optimise� it� for� the�partner’s�instrumentation.��To�date,�the�new�designs�have�hit�all�of�the�partner’s�target�design�criteria�and�passed�all�evaluations.�

Research�

April�2009:�In�a�retrospective�database�study,�carried�out�by�Healthscope�(Australia’s�third�largest�private�pathology�provider),�PapType�was�found�to�have�a�high�negative�predictive�value�when�compared�to�routine�Pap�smears.��That�is,�a�negative�result�on�PapType�means�that�a�patient�can�be�extremely�confident�that�she�does�not�have�cervical�pre�cancer.�

September�2009:�A�clinical�trial�of�almost�nine�hundred�patients�demonstrates�that�PapType�is�better�at�detecting�cervical�pre�cancers�in�women�with�abnormal�Pap�smears�than�the�global�market�leading�product.�

May�2010:�Genera�signed�a�development�agreement�with�Healthscope�Limited�for�the�design�and�development�of�a�test�which�is�capable�of�simultaneously�detecting�and�differentiating�twelve�different�viral�respiratory�tract�pathogens�(including�influenza�sub�types)�and�3�different�bacterial�respiratory�pathogens.��The�test�is�based�upon�the�same�proprietary�bead�based�platform�as�PapType.�

Regulatory�

October�2009:�The�Company�was�granted�a� licence�to�manufacture� in�vitro�diagnostic�devices�by�the�Australian�Therapeutic�Goods�Administration�(TGA).�

January� 2010:� PapType� became� the� first� HPV� test� to� be� listed� on� the� Australian� Register� of�Therapeutic�Goods.�

April�2010:�PapType�is�CE�IVD�marked.�

15

For

per

sona

l use

onl

y

Page 17: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

THE�WAY�FORWARD�2011�

The�next�major�milestone�with�the�global�R&D�partner�will�be�the�results�of�a�clinical�evaluation,�being�carried�out�on�approximately�300�patients.��Clinical�specimens�from�these�patients�will�be�tested�using�the�modified�HPV�test�provided�by�Genera�to�the�partner,�as�well�as�two�other�reference�HPV�testing�methodologies�–�Hybrid�Capture�2�manufactured�by�Qiagen,�and�Linear�Array�HPV�manufactured�by�Roche.��The�study�is�expected�to�be�completed�in�early�April,�and�results�will�be�available�shortly�thereafter.��This�will�be�the�formal�close�of�the�initial�round�of�R&D�with�our�partner.��Following�on�from�the�successful�completion�of�the�initial�R&D,�the�Company�will�be�in�a�position�to�take�the�next�steps�to�commercialisation�with�its�partner.��In�particular,�this�will�involve�instrument�prototyping�by�the�partner�and�in�market�testing,�for�which�Genera�will�be�supplying�large�quantities�of�HPV�tests.��It�is�anticipated�that�the�in�market�evaluation�will�be�conducted�in�the�USA,�Europe�and�China.��Based�on�currently�available�information,�the�Directors�anticipate�the�in�market�testing�to�be�completed�in�March�2012,�after�which�time,�Genera�reasonably�expects�to�be�in�a�position�to�conclude�a�commercialisation�agreement�for�the�HPV�test.��The�Company�also�plans�to�pursue�a�commercialisation�strategy�independent�of�its�partner.��To�that�end,�the�Company�plans�to�conduct�two�clinical�trials�with�high�profile�laboratories�in�the�United�Kingdom.��These�trials�will�provide�valuable�data�for�profiling�PapType,�both�to�potential�end�users,�as�well�as�other�prospective�commercialisation�partners.��Whilst�feedback�from�potential�customers�of�PapType�has�generally�been�positive,�users�have�noted�that,�in�a�time�of�tightening�pathology�margins,�uptake�would�likely�be�enhanced�by�provision�of�an�automated�instrument�platform.��The�Company�has�therefore�formulated�plans�for�the�development�of�its�own�automated�platform,�known�as�The�Beach.��This�instrument�will�automate�all�of�the�key�handling�steps�and�processes�required�to�successfully�run�a�Genera�test.��Development�will�commence�upon�receipt�of�sufficient�capital.��

In�order�to�increase�the�prospects�for�uptake�of�The�Beach,�a�high�value�menu�is�required.��As�such,�in�addition�to�PapType�(subject�to�whatever�agreement�is�finally�reached�with�the�development�partner),�the�Company�will�finalise�the�development�of�its�RTI�plex�product�and�apply�for�regulatory�approval�where�possible.��In�addition,�the�Company�has�plans�for�other�high�value�multiplexed�tests,�such�as�STI�plex,�capable�of�detecting�and�differentiating�multiple�different�sexually�transmitted�diseases.�

2.2�Effect�on�the�Company’s�financial�position�

To�illustrate�the�effect�of�the�Offer�on�the�Company,�a�Pro�Forma�Statement�of�Financial�Position�has�been�prepared�as�at�31�December�2010�which�is�set�out�in�section�6.���

16

For

per

sona

l use

onl

y

Page 18: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

3� RISK�FACTORS�

3.1 General�market�risks�

Shareholders�should�be�aware�that�the�market�price�of�the�Genera�securities�may�be� influenced�by�a�number� of� factors.� � General� movements� in� local� and� international� stock� markets,� exchange� rates,�prevailing�economic�conditions,�investor�sentiment�and�interest�rates�could�all�affect�the�market�price�of�the�Company’s�securities.��These�risks�apply�generally�to�any�investment�on�the�stock�market.�

In�addition�to�the�general�risks�associated�with�investing�in�the�stock�market,�there�are�risks�specific�to�investing� in� any�particular� entity.� � If� in� doubt� about� the� general� or� specific� risks� associated�with� the�Company’s�securities,�you�should�seek�advice�from�your�professional�advisors.�

Offer�speculative�

The� New� Securities� offered� under� this� Prospectus� should� be� regarded� as� speculative� due� to� the�inherent� risks� associated� with� the� Company’s� activities.� � Neither� the� Company� nor� the� Directors�warrant�the�future�performance�of�the�Company�or�any�investment�made�pursuant�to�this�Prospectus.�

The� Directors� recommend� that� Shareholders� and� potential� investors� examine� the� contents� of� this�document�together�with�previous�ASX�disclosures�and�public�documents�of�the�Company,�including�its�most� recent� audited� financial� statements,� and� rely� on� advice� of� their� professional� advisers� before�deciding� whether� or� not� to� apply� for� New� Securities� pursuant� to� this� Prospectus.� � The� following�summary,�which�is�not�exhaustive,�represents�some�of�the�major�risk�factors�which�potential�investors�need�to�be�aware�of.�

Options�

The�value�of�Options� is�dependant�on�a�number�of� factors� including� time� to�expiry,�underlying�share�price,� option� exercise� price,� the�underlying� share�price� volatility� and� the� illiquidity� of� the�market� for�Option,�particularly�where�the�Options�are�not�quoted.��The�value�of�Option�prices�can�rise�and�fall,�and�at� any� given� time�Options� can�be� ‘in� the�money’�or� ‘out�of� the�money’.��Options� can�expire�with�no�value.��Investors�should�be�aware�that�an�Option�may�return�little�or�no�value.�

�3.2 Company�Specific�Risks�

Whilst�Genera�has�successfully�brought�products�to�market�in�the�past,�there�is�no�guarantee�that�it�will�be�able�to�do�so�successfully�in�the�future.��Specific�risks�in�product�development�include:�

� Experimental�failure��Central�to�Genera’s�product�offering�is�that�its�tests�are�multiplexed�–�that�is,�they�have�the�capability�to�detect�multiple�different�targets�simultaneously.��However,�the�process�of�optimising�a�multiplex�test�is�very�complex,�and�it�may�not�be�possible�ultimately�to�combine�all�of�the�target�analytes�into�a�single�assay.��

17

For

per

sona

l use

onl

y

Page 19: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

� IP�risk�In�respect�of�PapType,�Genera�has�had�key�aspects�of�the�product’s�biochemistry�reviewed�by�a�US�firm�of�patent�attorneys,�the�result�of�which�was�a�Freedom�to�Operate�report.��However,�this�report�does�not�prevent�the�Company�or�the�product�from�being�the�subject�of�a�lawsuit�in�respect�of�patent�infringement.�

In�respect�of�other�assays,�the�Company�will�seek�to�work�around�any�existing�IP,�or�reach�commercial�agreements�with�other�IP�holders�in�order�to�bring�new�tests�to�market.��However,�it�is�possible�that�appropriate�freedom�to�operate�may�not�be�secured�for�future�tests.��

� Partner�withdrawal�All�of�the�work�that�Genera�has�done�to�date�in�respect�of�the�agreement�that�it�has�with�its�partner�has�been�successful.��The�Company�has�designed�two�alternative�tests,�which�have�hit�the�partner’s�target�specifications.��Those�tests�have�been�successfully�manufactured�in�Genera’s�Melbourne�factory�and�experiments�indicate�that�both�alternative�designs�have�characteristics�which�make�them�equivalent�to�the�PapType�test�currently�approved�by�the�TGA.��However,�some�of�the�remaining�development�work�prior�to�a�final�product�relies�upon�the�partner�being�able�to�successfully�engineer�its�instrumentation.��This�work�is�outside�of�Genera’s�expertise�and�influence.��Moreover,�the�partner�may�change�its�commercial�strategy,�and�elect�not�to�pursue�the�cervical�screening�market.��

Future�capital�requirements�

There� can�be�no�guarantees� that� the� funds� raised� through� the�Offer�will�be� sufficient� to� successfully�achieve�all�the�objectives�of�the�Company’s�overall�business�strategy.��It�is�likely�that�the�Company�will�need�significant�additional�capital�to�fund�its�ongoing�product�and�technology�development�programs.��If�the�Company�is�unable�to�use�debt�or�equity�to�fund�expansion�after�the�substantial�exhaustion�of�the�net� proceeds� of� the�Offer� there� can� be� no� assurances� that� the� Company�will� have� sufficient� capital�resources�for�that�purpose,�or�other�purposes,�or�that�it�will�be�able�to�obtain�additional�resources�on�terms�acceptable�to�the�Company�or�at�all.�

Genera�may� seek� to� obtain� funding� by� issuing� additional� Shares,� borrowing�money� or� entering� into�collaborative� agreements.� � Any� additional� equity� financing�may� be� dilutive� to� Shareholders� and� any�debt�financing�if�available�may�involve�restrictive�covenants,�which�may�limit�the�Company’s�operations�and�business�strategy.�

The� Company’s� failure� to� raise� capital� if� and� when� needed� could� delay� or� suspend� the� Company’s�business�strategy�and�could�have�a�material�adverse�effect�on�the�Company’s�activities.�

Retention�of�key�personnel�

Because� of� the� specialised� nature� of� Genera’s� business,� the� Company� is� highly� dependent� upon�qualified,� technical� and� managerial� personnel� to� continue� to� develop� the� technology� and� the�Company’s�products.��

18

For

per

sona

l use

onl

y

Page 20: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

Genera�may�not�be�able�to�attract�and�retain�the�qualified�personnel�necessary�for�the�development�of�its�business.��The�loss�of�the�services�of�existing�personnel,�as�well�as�the�failure�to�recruit�additional�key�technical,�managerial�and�other�personnel�in�a�timely�manner�could�harm�the�Company’s�development�and�commercialisation�activities.�

Competition�

Competition�exists�in�the�industries�in�which�the�Company�operates,�including�competition�related�to:�

� Developing�products�for�existing�and�new�markets;�

� Obtaining�and�sustaining�proprietary�rights�to�technology;�and�

� Marketing,�selling�and�distributing�products.�

The�Company�faces�competitors�in�each�of�its�markets�that�are�much�larger�organisations,�which�could�use�their�size�to�exert�pressure�in�the�markets�in�which�the�Company�operates,�particularly�in�respect�to�pricing.��The�ability�of�a�current�or�new�competitor�to�introduce�an�improved�product�is�also�a�continual�competitive�threat�that�could�adversely�impact�on�the�Company’s�financial�performance.�

Such�competition�and�new�technologies�can�have�the�effect�of:�

� Rendering�costly�research�and�development�obsolete;�

� Decreasing�the�financial�value�of�products�or�research�projects;�and�

� Reducing�pricing�and�profit�margins.�

Technology�

The�Company’s� future� success�will� depend�on� its� ability� to� enhance� its� existing�product� and�develop�new�products�so�that�it�can�compete�in�a�global�market�place.��This�will�require�management�to�remain�at� the� forefront�of� technological� developments� in� the� industry.� � There� can�be�no�assurance� that� the�Company� will� successfully� develop� and� manufacture� new� products� or� that� new� products� will� be�accepted� in� the� market� place.� � If� the� Company� does� not� successfully� introduce� new� products,� the�business,�operating�results�and�financial�condition�of�the�Company�may�be�adversely�affected.�

The�Directors�believe� that� the�Company� is� in�a�position� to�keep� itself� abreast�of�major� technological�developments.��However,�it�is�difficult�to�predict�which�developments�will�have�a�major�impact�on�the�market.� � The� Company� has� to� decide� and� direct� its� resources� accordingly.� � Some� decisions� on� the�perceived� significance� of� the� technology� and� its� relevance� to� the� market� may� be� incorrect.� � If� the�Company�does�not�direct�is�resources�accordingly,�the�ability�of�the�Company�to�compete�in�the�future�will�be�adversely�affected.�

Risk�of�Product�Liability�

The� Company’s� business� exposes� it� to� potential� product� liability.� � The� Company� will� seek� to� obtain�adequate�product�liability� insurance�whenever�prudent.� �There�can�be�no�assurance�that�adequate�or�necessary�insurance�coverage�will�be�available�at�an�acceptable�cost�or�in�sufficient�amounts,�if�at�all,�or�that�a�product�liability�or�other�claim�would�not�materially�and�adversely�affect�the�business�or�financial�condition�of�the�Company.�

19

For

per

sona

l use

onl

y

Page 21: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

4 ACTION�REQUIRED�BY�ELIGIBLE�SHAREHOLDERS�

Important�Notice�

The� Offer� is� non�renounceable� which� means� that� if� Shareholders� do� not� take� up� all� of� their�Entitlement,� their� unaccepted� Entitlement� will� lapse.� � � Shareholders� wishing� to� participate� should�either�accept�their�Entitlement,� in�whole�or� in�part,�as�outlined�below.� � �Eligible�Shareholders�do�not�need� to� take� up� their� full� Entitlement,� although� their� proportional� interest� in� the� Company� will� be�diluted�if�they�choose�not�to�do�so.�

4.1 � Shareholders’�Entitlement�

All�persons�registered�as�Shareholders�on�the�Record�Date�will�be�Eligible�Shareholders�and�will�receive�an�Entitlement�of�one�(1)�Rights�Share�for�every�seven�(7)�Shares�held�on�that�date.��The�number�of�Rights�Shares�to�which�you�are�entitled�is�shown�on�the�Entitlement�and�Acceptance�Form.��In�addition,�for�each�Rights�Share�purchased,�a�Shareholder�will�be�entitled�to�a�bonus�issue�of�one�(1)�New�Option�at�no�cost,�exercisable�before�the�Expiry�Date�at�$0.33�each.�

4.2 � Offer�Price�

The�Offer�Price�for�the�Rights�Shares�is�$0.33�per�Share.�

4.3 � Entitlement�and�Acceptance�Form�

Each�Prospectus�sent�to�an�Eligible�Shareholder�will�include�a�personalised�Entitlement�and�Acceptance�Form.�

4.4 � Action�required�

4.4.1� If�you�wish�to�take�up�some�or�all�of�your�Entitlement:��

(a)�� Payment�by�cheque�or�bank�draft��

� Complete�the�accompanying�personalised�Entitlement�and�Acceptance�Form�in�accordance�with�the�instruction�on�the�Entitlement�and�Acceptance�Form;�and�

� Forward�your�completed�Entitlement�and�Acceptance�Form�together�with�your�cheque�or�bank�draft�in�Australian�currency�for�the�amount�shown�on�the�form,�to�the�following�address�to�be�received�no�later�than�5.00pm�(AEDT)�on�29�March�2011.�

Genera�Biosystems�Limited�C/o�Computershare�Investor�Services�Pty�Limited�GPO�Box�505�Melbourne,�Victoria�3001�Australia�

20

For

per

sona

l use

onl

y

Page 22: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

Cheques�must�be�made�payable�to�“Genera�Biosystems�Rights�Issue�Account”�and�crossed�‘Not�Negotiable’.�

Entitlement�and�Acceptance�Forms�(and�Application�Monies)�will�not�be�accepted�at�the�Company's�registered�office�or�corporate�offices,�or�any�offices�of�the�Share�Registry.�

Cash�payments�will�not�be�accepted.��Receipts�for�payment�will�not�be�issued.�

You�should�ensure�that�sufficient�funds�are�held�in�relevant�account(s)�to�cover�the�Application�Monies�as�your�cheques�will�be�processed�on�the�day�of�receipt.��If�the�amount�of�your�cheque�for�Application�Monies�(or�the�amount�for�which�the�cheque�clears�in�time�for�allocation)�is�insufficient�to�pay�in�full�for�the�number�of�Rights�Shares�you�have�applied�for�on�your�Entitlement�and�Acceptance�Form,�you�will�be�taken�to�have�applied�for�such�lower�number�of�whole�Rights�Shares�as�your�cleared�Application�Monies�will�pay�for�(and�to�have�specified�that�number�of�Rights�Shares�on�your�Entitlement�and�Acceptance�Form).��Alternatively,�your�Application�will�not�be�accepted.�

(b)� Payment�by�BPAY��

For�payment�by�BPAY,�please�follow�the�instructions�on�the�Entitlement�and�Acceptance�Form�(which�includes�the�Biller�Code�and�your�unique�Customer�Reference�Number).��You�can�only�make�payment�via�BPAY�if�you�are�the�holder�of�an�account�with�an�Australian�financial�institution�that�supports�BPAY�transactions.�

Please�note�that�should�you�choose�to�pay�by�BPAY:�

� you�do�not�need�to�submit�the�Entitlement�and�Acceptance�Form�but�are�taken�to�make�the�declarations�on�that�Entitlement�and�Acceptance�Form;�and��

� if�you�do�not�pay�for�your�full�Entitlement,�you�are�deemed�to�have�taken�up�your�Entitlement�in�respect�of�such�whole�number�of�Rights�Shares�which�is�covered�in�full�by�your�Application�Monies.�

It�is�your�responsibility�to�ensure�that�your�BPAY�payment�is�received�by�no�later�than�5.00�pm�AEDT�on�29�March�2011.��You�should�be�aware�that�your�financial�institution�may�implement�earlier�cut�off�times�with�regards�to�electronic�payment,�and�you�should�therefore�take�this�into�consideration�when�making�payment.�

Please�make�sure�to�use�the�specific�Biller�Code�and�unique�Customer�Reference�Number�on�your�Entitlement�and�Acceptance�Form.��If�you�received�more�than�one�Entitlement�and�Acceptance�Form,�you�will�need�to�complete�individual�BPAY�transactions�using�the�Customer�Reference�Number�specific�to�each�individual�Entitlement�and�Acceptance�Form�that�you�receive.��If�you�inadvertently�use�the�same�Customer�Reference�Number�for�more�than�one�of�your�Entitlements,�you�will�be�deemed�to�have�applied�only�for�your�Entitlement�to�which�that�Customer�Reference�Number�applies�and�any�excess�amount�will�be�refunded.�

4.4.2� If�you�wish�to�apply�for�Top�Up�Shares�in�excess�of�your�Entitlement�

Complete�the�accompanying�personalised�Entitlement�and�Acceptance�Form�in�accordance�with�the�instruction�on�the�Entitlement�and�Acceptance�Form�or�alternatively�pay�using�BPAY�in�accordance�with�the�instructions�on�the�Entitlement�and�Acceptance�Form�accompanying�this�Prospectus.�

21

For

per

sona

l use

onl

y

Page 23: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

4.5 Entitlements�not�accepted�

If�you�decide�not�to�accept�all�or�part�of�your�Entitlement,�your�unaccepted�Entitlement�will�lapse.��It�is�important�that�you�take�action�to�accept�your�Entitlement�in�accordance�with�the�above�instruction�to�avoid�it�lapsing�and�your�shareholding�being�diluted�by�the�issue�of�Rights�Shares�and�New�Options�under�the�Offer.�

4.6 Taxation�considerations�

General�Information�only�

It�is�your�responsibility�to�satisfy�yourself�of�the�particular�taxation�treatment�that�applies�to�you�by�consulting�your�own�professional�tax�advisor�on�your�specific�circumstances�before�taking�up�your�Entitlements.�

Taxation�consequences�depend�on�your�particular�circumstances�

Neither�Genera�nor�any�of�its�officers,�employees,�agents�and�advisors�accept�any�liability�or�responsibility�in�respect�of�the�taxation�consequences�resulting�from�an�investment�in�or�disposal�of�or�exercise�of�(if�applicable)�the�Rights�Shares�or�New�Options.�

You�should�seek�your�own�professional�taxation�advice.�

4.7 Enquiries�

If�you�have�any�questions�concerning�your�Entitlement�or�the�Offer,�you�should�contact�the�Genera�Biosystems�Information�Line�on�1300�055�821�(local�call�cost�within�Australia)�or�+61�3�9415�4664�(from�outside�Australia)�at�any�time�from�8.30am�to�5.00pm�Monday�to�Friday,�or�your�stockbroker,�financial�or�other�professional�adviser.�

22

For

per

sona

l use

onl

y

Page 24: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

5��� ADDITIONAL�STATUTORY�INFORMATION�

5.1������Rights�Attaching�to�New�Options�

� The�New�Options�will�expire�at�5.00pm�(AEST)�on�8�April�2013�(Expiry�Date).��New�Options�not�exercised�on�that�date�will�lapse.�

� There�is�no�obligation�to�exercise�the�New�Options.�

� The�Exercise�Price�or�number�of�New�Options�issued�may�be�changed�in�accordance�with�Listing�Rule�6.22�or�any�amendment�of�that�Rule�from�time�to�time.�

� In�the�event�of�any�reconstruction�(including�a�consolidation,�sub�division,�reduction�or�return)�of�the�issued�capital�of�the�Company,�the�rights�of�the�New�Option�holder�will�be�changed�to�the�extent�necessary�to�comply�with�the�Listing�Rules�applying�to�a�reorganisation�of�capital�at�the�time�of�the�reorganisation.�

� A�New�Option�has�no�right�to�participate�in�a�new�issue�of�Shares�in�the�Company�unless�that�Option�has�been�exercised.�

� To�exercise�a�New�Option,�the�holder�must�complete�and�execute�a�Notice�of�Exercise�of�Option�in�the�form�that�will�be�forwarded�to�all�New�Options�holders�following�allotment,�and�must�lodge�the�completed�notice�and�payment�of�the�Exercise�Price�at�the�Company’s�registered�office�or�otherwise�directed�at�any�time�prior�to�the�Expiry�Date.�

� The�Exercise�Price�of�each�New�Option�will�be�$0.33.�

� Option�holders�will�be�issued�one�(1)�Share�in�the�Company�within�20�Business�Days�of�a�New�Option�being�duly�exercised.��

� Shares�issued�on�exercise�of�the�New�Options�will�rank�equally�in�all�respects�with�other�Shares�on�issue�at�that�time.��The�rights�and�liabilities�attaching�to�the�Shares�issued�upon�exercise�of�the�New�Options�are�set�out�under�paragraph�5.2�below.�

� The�Company�will�apply�for�Official�Quotation�by�ASX�of�the�Shares�issued�upon�exercise�of�the�New�Options�within�3�Business�Days�of�allotment�of�the�Shares.�

5.2���Rights�and�Liabilities�Attaching�to�Rights�Shares�

A�summary�of�the�rights�which�relate�to�Shares�is�set�out�below��This�summary�does�not�purport�to�be�exhaustive�or�constitute�a�definitive�statement�of�the�rights�and�liabilities�of�the�Company’s�Shareholders.��Full�details�of�the�rights�attaching�to�the�Shares�are�set�out�in�the�Constitution�of�the�Company,�a�copy�of�which�can�be�inspected�at�the�Company’s�registered�office�during�normal�business�hours.�

� Subject�to�any�special�rights�or�restrictions�for�the�time�being�attached�to�any�class�or�classes�of�shares�in�the�Company�(at�present�there�are�none),�at�a�general�meeting�every�Shareholder�present�in�person�or�by�proxy,�representative�or�attorney�will�have�a�vote�on�a�show�of�hands�and,�on�a�poll,�one�vote�for�each�Share�held.�

23

For

per

sona

l use

onl

y

Page 25: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

� Each�Shareholder�will�be�entitled�to�receive�notice�of,�and�to�attend�and�vote�at,�general�meetings�of�the�Company�and�to�receive�all�notices,�accounts�and�other�documents�required�to�be�furnished�to�Shareholders�under�the�Constitution�or�the�Corporations�Act.�

� The�Board�may�from�time�to�time�determine�that�a�dividend�is�payable�to�Shareholders.��The�dividend�is�(subject�to�the�rights�of,�or�any�restriction�on,�the�holders�of�shares�created�or�raised�under�any�special�arrangement�as�to�dividend)�payable�on�all�Shares�in�proportion�to�the�total�offer�price�for�the�time�being�paid�or�credited�as�paid,�and�may�be�paid�at�a�rate�per�annum�in�respect�of�a�specified�period�provided�that�no�amount�paid�on�a�Share�in�advance�of�calls�is�to�be�treated�as�paid�on�that�Share.�

� If�the�Company�is�wound�up,�whether�voluntarily�or�otherwise,�the�liquidator�may�divide�among�all�or�any�of�the�contributories�as�the�liquidator�thinks�fit�in�specie�or�in�kind�any�part�of�the�assets�of�the�Company,�and�may�vest�any�part�of�the�assets�of�the�Company�in�trustees�upon�any�trusts�for�the�benefit�of�all�or�any�of�the�contributories�as�the�liquidator�thinks�fit.�

� Without�prejudice�to�any�special�rights�conferred�on�the�holders�of�any�shares,�and�subject�to�the�Listing�Rules,�any�share�in�the�capital�of�the�Company�may�be�issued�with�preferred,�deferred�or�other�special�rights,�obligations�or�restriction,�whether�in�regard�to�dividends,�voting,�return�of�share�capital,�payment�of�calls�or�otherwise,�as�the�Board�may�from�time�to�time�determine.�

� The�rights�attached�to�any�class�of�shares�(unless�otherwise�provided�by�the�terms�of�issue�of�the�shares�of�that�class)�may,�whether�or�not�the�Company�is�being�wound�up,�and�subject�to�the�Listing�Rules,�be�varied�with�the�consent�in�writing�of�members�with�at�least�75%�of�the�votes�in�the�class,�or�with�the�sanction�of�a�special�resolution�passed�at�a�separate�meeting�of�the�holders�of�the�shares�of�that�class.�

� As�the�Company�participates�in�CHESS,�the�ASTC�Settlement�Rules�govern�the�transfer�of�shares�including�market�settlement�and�securities�transfer�and�registration.�

� The�Constitution�of�the�Company�can�only�be�amended�by�a�special�resolution,�passed�by�at�least�three�quarters�of�the�votes�cast�by�holders�of�shares�entitled�to�vote�on�the�resolution,�at�a�general�meeting.��At�least�28�days’�written�notice�specifying�the�intention�to�propose�the�resolution�as�a�special�resolution�must�be�given.�

24

For

per

sona

l use

onl

y

Page 26: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

6. FINANCIAL�INFORMATION�

This�Financial�information�section�consists�of�the�audited�Statement�of�Financial�Position�as�at�30�June�2010,�the�reviewed�Statement�of�Financial�Position�as�at�31�December�2010�and�the�Pro�Forma�Statement�of�Financial�Position�as�at�31�December�2010.���The�Pro�Forma�Statement�of�Financial�Position�incorporates�adjustments�to�the�reviewed�Statement�of�Financial�Position�as�at�31�December�2010�for�the�impacts�of�the�Offer�on�cash�assets�and�contributed�capital�after�estimated�Offer�Costs.�

30 June 2010 Audited

31 December 2010 Reviewed

31 December 2010 Pro-forma

STATEMENTS OF FINANCIAL POSITION

$ $ $

Current Assets

Cash and cash equivalents 2,601,724 1,295,740 4,184,328

Trade and other receivables 167,154 52,632 52,632

Inventories 57,333 45,225 45,225

Current tax assets 663,380 309,833 309,833

Other current assets 81,478 63,096 63,096

Total Current Assets 3,571,069 1,766,526 4,655,114

Non-Current Assets

Plant and equipment 273,258 292,777 292,777

Deferred tax assets 457,948 470,192 470,192

Development costs 2,917,414 2,786,469 2,786,469

Intangible assets 1,638,845 1,660,818 1,660,818

Total Non-Current Assets 5,287,465 5,210,256 5,210,256

Total Assets 8,858,534 6,976,782 9,865,370

Current Liabilities

Trade and other payables 557,201 545,296 545,296

Provisions 188,273 191,761 191,761

Borrowings 67,109 22,370 22,370

Total Current Liabilities 812,583 759,427 759,427

Non-current Liabilities

Deferred tax liabilities 457,948 470,192 470,192

Provisions 38,652 46,691 46,691

Total Non-current Liabilities 496,600 516,883 516,883

Total Liabilities 1,309,183 1,276,310 1,276,310

Net Assets 7,549,351 5,700,472 8,589,060

Equity

Issued Capital 19,353,856 19,353,856 22,242,444

Share Option reserve 836,948 777,848 777,848

Accumulated losses (12,641,453) (14,431,232) (14,431,232)

Total Equity 7,549,351 5,700,472 8,589,060

25

For

per

sona

l use

onl

y

Page 27: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

Notes�to�the�Financial�Information�

(i) Audited�and�Reviewed�Statements�of�Financial�Position�

The�Statements�of�Financial�Position�shown�above�have�been�extracted�from,�respectively:�

Statement�of�Financial�Position:� Extracted�from:�

30�June�2010�Audited� Annual�Report�

31�December�2010�Reviewed� Half�Year�Report�

31�December�2010�Pro�forma� Refer�“(ii)�Pro�Forma�Assumptions”,�below.��This�Statement�of�Financial�Position�has�not�been�audited�or�reviewed�by�the�Company’s�Auditor.�

(ii) Pro�Forma�Assumptions�and�notes�

The�Pro�Forma�Balance�Sheet�has�been�prepared�on�the�following�assumptions:�

� the�Offer�is�fully�subscribed;�

� the�estimated�amount�of�Offer�Costs,�as�disclosed�in�section�8.3,�is�fully�incurred;�

� the�Pro�Forma�Statement�of�Financial�Position�incorporates�adjustments�to�the�reviewed�Statement�of�Financial�Position�as�at�31�December�2010�which�reflect�the�assumed�impacts�of�the�Offer�on�cash�assets�and�contributed�capital�after�estimated�Offer�Costs;�

� any�financial�effect�of�any�exercise�of�the�New�Options�is�not�included.�

(iii)Maximum�amount�which�may�be�raised�from�the�issue�of�Rights�Shares�

The�exact�maximum�dollar�amount�which�may�be�raised�from�the�issue�of�all�Rights�Shares�pursuant�to�the�Offer�cannot�be�precisely�calculated�at�this�point�in�time.��A�theoretical�amount�can�be�calculated�as�follows:�

Shares�currently�on�issue�(62,670,279)�divided�by�7,�and�multiplied�by�Offer�Price�($0.33)�

=�$2,954,445.01�

However�this�does�not�take�into�account�any�roundings�up�which�may�arise�when�calculating�individual�Eligible�Shareholders’�Entitlements�(refer�section�1.5�of�this�Prospectus).��These�roundings�up�are�not�expected�to�have�a�material�effect.�

For�convenience,�references�in�this�Prospectus�to�the�maximum�amount�which�may�be�raised�from�the�issue�of�all�Rights�Shares,�and�New�Options,�have�been�rounded�to�$2.95�million.�

26

For

per

sona

l use

onl

y

Page 28: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

REPORTING�AND�DISCLOSURE�

7.1 Continuous�reporting�and�disclosure�obligations�

This�Prospectus�is�issued�pursuant�to�section�713�of�the�Corporations�Act�as�a�prospectus�for�the�offer�of�continuously�quoted�securities.�

The�Company�is�a�‘disclosing�entity’�for�the�purposes�of�the�Corporations�Act�and�as�such�is�subject�to�regular�reporting�and�disclosure�obligations.��Specifically,�as�a�listed�company,�Genera�is�subject�to�the�Listing�Rules�which�require�continuous�disclosure�of�any�information�the�Company�has�to�ASX�which�a�reasonable�person�would�expect�to�have�a�material�effect�on�the�price�or�value�of�its�Shares.�

Copies�of�ASX�announcements�are�available�on�the�ASX�website�or�the�Company’s�website�at�www.generabiosystems.com�

In�addition,�copies�of�documents�lodged�with�ASIC�in�relation�to�the�Company�may�be�obtained�from,�or�inspected�at,�an�office�of�ASIC.�

The�Company�will�provide�free�of�charge,�to�any�person�who�requests�it�during�the�application�period�under�this�Prospectus,�a�copy�of�the�Annual�Report,�a�copy�of�the�Half�Year�Report,�and�any�continuous�disclosure�notices�lodged�by�the�Company�as�listed�in�section�7.2�below.�

7.2 List�of�ASX�Announcements�

Date� Announcement�

24�February�2011� Half�Yearly�Report�and�Accounts�

23�February�2011� Commercialisation�Update,�Capital�Raising�Update �

21�February�2011� Trading�Halt�

31�January�2011� Appendix�4C���quarterly��

27�January�2011� Becoming�a�substantial�holder��

6�January�2011� Milestone�payment�received�from�partner��

20�December�2010� Securities�Trading�Policy��

3�December�2010� Change�of�Director’s�Interest�Notice��

25�November�2010� Initial�Director’s�Interest�Notice��

25�November�2010� Initial�Director’s�Interest�Notice��

25�November�2010� Final�Director’s�Interest�Notice��

25�November�2010� Director�Retirement/Appointments��

25�November�2010� Results�of�Meeting��

25�November�2010� AGM�CEO�Presentation��

25�November�2010� Chairman’s�Address�to�Shareholders��

29�October�2010� Appendix�4C���quarterly��

27

For

per

sona

l use

onl

y

Page 29: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

22�October�2010� Notice�of�Annual�General�Meeting/Proxy�Form��

8�October�2010� Board�appointments�and�Director�retirement��

29�September�2010� Annual�Report�to�shareholders��

28�September�2010� Date�of�Annual�General�Meeting�

16�September�2010� Company�Secretary�Appointment/Resignation��

6�September�2010� Change�in�substantial�holding��

30�August�2010� Appendix�4E�Preliminary�Final�Report��

10�August�2010� Lapsed�Options��

23�July�2010� Appendix�4C���quarterly �

28

For

per

sona

l use

onl

y

Page 30: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

8 ADDITIONAL�INFORMATION�

8.1 Consents�and�disclaimers�of�responsibility�

Each�of�the�Directors�of�Genera�has�consented�to�the�lodgement�of�this�Prospectus�with�ASIC.�

Grant�Thornton�Audit�Pty�Ltd�has�given,�and,�as�at�the�date�hereof,�has�not�withdrawn,�its�written�consent�to�being�named�as�auditor�for�the�Company�in�the�form�and�context�in�which�it�is�named.��Grant�Thornton�Audit�Pty�Ltd�has�not�caused�or�authorised�the�issue�of�this�Prospectus�and�takes�no�responsibility�for�any�part�of�this�Prospectus.�

Computershare�Investor�Services�Pty�Limited,�has�given,�and�has�not�withdrawn�its�written�consent�to�being�named�as�Share�Registrar�in�the�form�and�context�in�which�it�is�named.�

Computershare�Investor�Services�Pty�Limited�has�had�no�involvement�in�the�preparation�of�any�part�of�the�Prospectus�other�than�being�named�as�Share�Registrar�to�the�Company.��Computershare�Investor�Services�Pty�Limited�has�not�authorised�or�caused�the�issue�of,�and�expressly�disclaims�and�takes�no�responsibility�for,�any�part�of�the�Prospectus.�

8.2 Experts�and�advisers�interests�

Other�than�as�set�out�below�or�elsewhere�in�this�Prospectus,�no�expert�or�any�firm�in�which�any�expert�is�a�partner�has,�or�has�had�in�the�two�years�before�lodgement�of�this�Prospects,�any�interest�in�the�promotion�of,�or�in�any�property�proposed�to�be�acquired�by�Genera�and�no�amounts,�whether�in�cash�or�shares�or�otherwise,�have�been�paid�or�agreed�to�be�paid�to�any�expert�(or�to�any�firm�in�which�he�or�she�is�or�was�a�partner)�for�services�rendered�by�the�expert�of�the�firm�in�connection�with�the�promotion,�or�was�a�director�of�Genera.��No�form�of�payment�of�any�kind�will�be�made�or�agreed�to�be�made�to�any�such�expert�or�firm�other�than�in�cash.�

8.3 Offer�Costs�

All�Offer�Costs,�comprising�expenses�connected�with�the�Offer�are�payable�by�Genera.�

Estimated�Offer�Costs�(net�of�GST),�assuming�the�Offer�is�fully�subscribed,�are:�

� $�Legal�fees� 25,000�Printing,�mailing� 8,800�Project�consulting� 20,000�ASX�Listing�fee� 8,800�ASIC�fee� 2,068�Other� 1,200�� �

Total� 65,868��

29

For

per

sona

l use

onl

y

Page 31: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

Although�the�Offer�is�not�underwritten,�the�Company�may�enter�into�arrangements�with�organisations�to�provide�assistance�in�relation�to�the�Offer�and�specifically�the�subscription�of�any�Shortfall�Shares.��Under�such�arrangements,�the�Company�may�be�required�to�pay�fees�or�commissions�on�appropriate�commercial�terms�for�that�assistance,�to�be�negotiated�by�the�Company�as�and�when�required.�

8.4 Interest�of�Directors�

Shareholdings�

As�at�the�date�of�this�Prospectus,�the�Directors�of�Genera,�their�associates�or�related�parties�have�a�relevant�interest�in�the�following�Shares�and�Options�in�Genera:�

Director� Shares� Options�

Entitlement�to�Rights�Shares�under�this�Prospectus�

Entitlement�to�New�Options�under�this�

Prospectus�

Mr�Fernando�Careri� 295,000 500,000 42,143� 42,143Dr�Karl�Poetter� 815,798 Nil 116,543� 116,543Mr�Jim�Kalokerinos� 35,000 Nil 5,000� 5,000Mr�Lou�Panaccio� Nil Nil Nil� NilMr�David�Symons� 526,045 550,000 75,150� 75,150Mr�Bill�Tapp� 2,361,790 Nil 337,399� 337,399�

The�Directors�reserve�the�right�to�take�up�their�Entitlements�under�the�Offer.�

Declaration�

Other�than�set�out�above�or�elsewhere�in�this�Prospectus:�

� No�Director�or�proposed�Director�of�Genera,�and�no�firm�in�which�a�Director�or�proposed�Director�of�Genera�is�or�was�at�the�relevant�time,�or�has�had�in�the�two�years�before�the�date�of�this�Prospects,�any�interest�in�the�formation�or�promotion�of,�or�in�any�property�proposed�to�be�acquired�by�Genera;�and�

� No�amounts,�whether�in�cash�or�shares�or�otherwise,�have�been�paid�or�agreed�to�be�paid�to�any�Director�or�proposed�Director�of�Genera�(or�to�any�firm�in�which�he�is�or�was�a�partner)�either�to�induce�him�to�become,�or�to�qualify�him�as�a�Director,�or�otherwise�for�services�rendered�by�him�or�by�the�firm�in�connection�with�the�promotion�or�formation�of�Genera,�or�in�connection�with�the�Offer.�

8.5 Privacy�

Upon�applying�for�Rights�Shares�and�New�Options�in�the�Company,�Applicants�will�be�required�to�provide�personal�information�to�Genera�directly�or�its�agents,�such�as�name,�address,�telephone/fax�numbers,�tax�file�number�and�account�details.��The�Company�or�its�agents�may�collect,�hold�and�use�that�personal�information�to�assess�Applications,�provide�facilities�and�services�to�Applicants�and�undertake�appropriate�administration.��Access�to�information�may�be�disclosed�by�the�Company�to�its�agents�and�service�providers�on�the�basis�that�they�deal�with�such�information�in�accordance�with�the�

30

For

per

sona

l use

onl

y

Page 32: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

Privacy�Act�1988�as�amended.��Applicants�may�request�access�to�their�personal�information�held�by�or�on�behalf�of�the�Company�by�contacting�it�as�set�out�in�the�Corporate�Directory.�

8.6� Applications�and�allotment�

The�Offer�must�be�carried�out�in�accordance�with�the�timetable�(as�amended�from�time�to�time),�the�Prospectus,�the�Corporations�Act,�the�Listing�Rules,�the�Constitution�of�the�Company�and�any�other�

applicable�law.�

31

For

per

sona

l use

onl

y

Page 33: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

9 DIRECTORS’�STATEMENT�

The�Directors�report�that,�after�due�enquiry�by�them,�they�have�not�become�aware�of�any�circumstances�which,�in�their�opinion,�will�materially�affect�the�assets�and�liabilities,�financial�position�and�performance,�profits�and�losses�or�the�prospects�of�Genera�other�than�as�disclosed�in�this�Prospectus.��

Dated�28�February�2011�

Signed�for�and�on�behalf�of�

Genera�Biosystems�Limited�

Fernando�Careri�

Chairman�

32

For

per

sona

l use

onl

y

Page 34: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

10 DEFINITIONS�

$� Australian�Dollars.�

ABN� Australian�Business�Number.�

AEDT� Australian�Eastern�Daylight�Time,�being�the�time�applicable�in�Melbourne,�Victoria,�Australia.�

AEST� Australian�Eastern�Standard�Time,�being�the�time�applicable�in�Melbourne,�Victoria,�Australia.�

Annual�Report� means�the�Annual�Report�and�Accounts�of�the�Company�for�the�financial�year�ended�30�June�2010�lodged�with�ASX�on�29�September�2010.�

Applicant� a�person�or�entity�who�submits�an�Entitlement�and�Acceptance�Form.�

Application� an�application�to�subscribe�for�Rights�Shares�under�this�Prospectus.�

Application�Monies� the�number�of�Rights�Shares�applied�for�multiplied�by�the�Offer�Price.�

ASIC� Australian�Securities�and�Investments�Commission.�

ASX� ASX�Limited�ABN�98�008�624�691.�

Board� the�board�of�directors�of�the�Company.�

Business�Day�� a�day�on�which�the�ASX�is�open�for�trading.�

CHESS� Clearing�House�Electronic�Subregister�System,�operated�by�ASX�Settlement�Pty�Limited.�

Closing�Date� the�date�on�which�the�Offer�closes,�being�5.00pm�(AEDT)�on�29�March�2011.�This�date�may�be�varied�without�prior�notice�by�the�Company.�

Company�or�Genera� Genera�Biosystems�Limited�ACN�098�663�837.�

Constitution� means�the�constitution�of�the�Company.�

Corporations�Act� the�Corporations�Act�2001�(Cth).�

Directors�� the�directors�of�Genera.�

Eligible�Shareholders� Shareholders�recorded�in�the�Company’s�share�register�on�the�Record�Date�as�having�a�registered�address�in�Australia�or�New�Zealand.�

Entitlement� the�right�of�Eligible�Shareholders�to�subscribe�for�one�(1)�Rights�Share�for�every�seven�(7)�Shares�held�on�the�Record�Date�plus�one�(1)�bonus�New�Option�at�no�cost�for�every�Right�Share�subscribed�for�in�accordance�with�the�Offer.�

33

For

per

sona

l use

onl

y

Page 35: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

Entitlement�and�Acceptance�Form�

a�Shareholder’s�personalised�Entitlement�and�Acceptance�Form�accompanying�this�Prospectus.�

Exercise�Price� $0.33�per�New�Option�to�acquire�a�Share.�

Existing�Options� the�options�over�fully�paid�ordinary�Shares�that�are�already�issued�to�Shareholders�which�have�not�been�exercised�and�have�not�expired�yet.��The�Existing�Options�are�not�listed�on�ASX.�

Expiry�Date� 5.00pm�(AEST)�on�8�April�2013.�

GBI� means�Genera’s�ASX�code�name.�

Half�Year�Report� means�the�Half�Yearly�Report�and�Accounts�of�the�Company�for�the�six�month�period�ended�31�December�2010�lodged�with�ASX�on�24�February�2011.�

Listing�Rules� the�Listing�Rules�of�ASX.�

New�Option� means�a�bonus�Option�over�a�Share�(with�an�Expiry�Date�of�8�April�2013�and�an�Exercise�Price�of�$0.33)�issued�at�no�cost�with�every�Rights�Share�subscribed�for�under�the�Offer.�

New�Securities� means�Rights�Shares�and�New�Options,�as�well�as�Top�Up�Shares,�offered�under�this�Prospectus.�

Offer� subject�to�the�terms�set�out�in�this�Prospectus,�the�non�renounceable�offer�of�up�to�the�following�New�Securities�to�Eligible�Shareholders�in�accordance�with�their�Entitlement:�

� 8,952,897�Rights�Shares;�and�

� 8,952,897�New�Options,�

(subject�to�minor�rounding�adjustments�in�accordance�with�this�Prospectus)�and�any�additional�New�Securities�applied�for�under�the�Top�Up�Facility.���

Offer�Costs� direct�costs�of�the�Offer�including�fees�paid�to��advisers�and�consultants�and�to�providers�of�specific�services�to�cover�printing�and�postage�costs.�

Offer�Price� $0.33�per�Rights�Share.�

Official�List� has�the�meaning�given�to�that�term�by�the�Listing�Rules.�

Official�Quotation� means�official�quotation�by�ASX.�

Opening�Date� 15�March�2011.�

34

For

per

sona

l use

onl

y

Page 36: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

Option� means�an�option�over�a�Share.�

Prospectus� means�this�document�as�amended�by�the�issue�of�any�supplementary�or�replacement�prospectus�from�time�to�time.�

R�&�D� research�and�development.�

Rights�Share� means�a�Share�offered�at�an�Offer�Price�of�$0.33�under�the�Offer.�

Record�Date� 7.00pm�(AEDT)�on�8�March�2011.�

SCH� Securities�Clearing�House.�

Shareholder� a�person�who�holds�a�Share�in�the�Company.�

Shares� fully�paid�ordinary�shares�in�the�Company.�

Shortfall�or�Shortfall�Shares� means�any�New�Securities�not�taken�up�by�Eligible�Shareholders�in�accordance�with�their�Entitlement�and�Top�Up�Shares�not�taken�up�under�the��Top�Up�Facility,�which�the�Board�reserves�the�right�to�place�within�3�months.�

Top�Up�Facility�� means�the�facility�described�in�section�1.4�under�which�Eligible�Shareholders�may�apply�for�Rights�Shares�and�bonus�attaching�New�Options�in�excess�of�their�Entitlement.�

Top�Up�Shares� means�extra�Rights�Shares�and�bonus�attaching�New�options�an�Eligible�Shareholder�may�apply�for�in�excess�of�their�Entitlement.�

35

For

per

sona

l use

onl

y

Page 37: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

36

11 CORPORATE�DIRECTORY�

Directors�

Mr�Fernando�Careri�(Chairman)��Dr�Karl�Poetter�(Executive�Director)�Mr�Jim�Kalokerinos�(Non�Exec.�Director)�Mr�Lou�Panaccio�(Non�Exec.�Director)�Mr�David�Symons�(Non�Exec.�Director)�Mr�William�Tapp�(Non�Exec.�Director)����

Chief�Executive�Officer�����������������������������������������

Dr�Allen�Bollands�������

Company�Secretary�and�Chief�Financial�Officer��

Mr�Tony�Panther�������

Registered�Office�

Small�Technologies�Cluster�1�Dalmore�Drive�SCORESBY��VIC��3179�

Auditor�

Grant�Thornton�Audit�Pty�Ltd�Level�2,�215�Spring�Street�MELBOURNE��VIC��3000�

Share�Register�

Computershare�Investor�Services�Pty�Limited�Yarra�Falls�452�Johnston�Street��ABBOTSFORD��VIC��3067�

������������������������� � � ���

For

per

sona

l use

onl

y

Page 38: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

1277

54_0

12JZ

G

2 N R B

Entitlement and Acceptance Form (including additional Top Up Shares)This personalised form:• is the Entitlement and Acceptance Form referred to in the accompanying Prospectus dated 28 February 2011 (“Prospectus”), issued by Genera Biosystems Limited

(the “Company”); and• can only be used in relation to the securityholding represented by the SRN or HIN printed above.Please read the Prospectus carefully. Words and terms appearing on this form have the same meaning as in the Prospectus, where applicable.This is an important document and requires your immediate attention. If you are in doubt about how to deal with this document, please consult your financial or other professional adviser.

ANon-renounceable Rights Issue of 1 Rights Share for every 7 Shares registered and entitled to participate at the Record Date (7:00pm (AEDT) on 8 March 2011), at an Offer Price of A$0.33 per Rights Share.With every one Rights Share taken up, Shareholders will be issued at no cost, a bonus New Option, which are exercisable for $0.33 each and expire at 5:00pm (AEST) on 8 April 2013.Eligible Shareholders may apply for Top Up Shares in excess of their Entitlement on the terms set out in the Prospectus.Your:• return of the Payment Slip below with a cheque, money order or bank draft for the payment

for Rights Shares and any Top Up Shares applied for; or• your BPAY payment for Rights Shares and any Top Up Shares applied for;in accordance with the instructions on this form will constitute:• your acceptance of the Offer in accordance with the terms and conditions of the Prospectus; and• your authorisation to be registered as the holder of any Shares and Options allotted to you

pursuant to the Offer.

Subregister

Existing Shares entitled to participate at Record Date on 8 March 2011

Entitlement to Rights Shares on a 1 for 7 basis

Entitlement to New Options

Entitlement Number

Securityholder Entitlement details

G B I

Number of Rights Shares applied for

PAYMENT SLIP

B

E

Amount of payment at A$0.33 per Rights Share plus any Top Up Shares applied for

.D

A$Number of Top Up Shares applied forC

See back of form for completion guidelines

Payment Details – Please note that funds are unable to be directly debited from your bank accountBSB number Cheque amount

A$

Account numberDrawer Cheque number

FMake your cheque, money order or bank draft payable to “Genera Biosystems Rights Issue Account” and crossed “Not Negotiable”.Contact DetailsPlease provide your contact details in case we need to speak to you about this slipName of contact person Contact person’s daytime telephone number

Please see overleaf for Payment Options

Please return completed form to:Computershare Investor Services Pty Limited

GPO Box 505 MelbourneVictoria 3001 Australia

Enquiries (within Australia) 1300 055 821(outside Australia) +61 3 9415 4664

Biller Code:Ref No:Paper clip

cheque(s) here.Do not staple.

Use a black pen. Print in CAPITAL letters inside the grey areas. A B C 1 2 3

▼ PLEASE DETACH HERE ▼

For your security keep your SRN/HIN confi dential.

Non-renounceable Rights Issue closing 5:00pm (AEDT) on 29 March 2011.

ABN 69 098 663 837

ABN 69 098 663 837

Amount payable on full acceptance at A$0.33 per Rights Share

123456 1234 5678 9012 3456 78

123456789012

XXX,XXX,XXX

XXX,XXX,XXX

XXX,XXX,XXX

Issuer

1234567890123456+1234567890-1234+12

I 1234567890 I N D

Securityholder Reference Number (SRN)

*I1234567890*

000001000SAM

MR JOHN SMITH 1FLAT 123123 SAMPLE STREETTHE SAMPLE HILLSAMPLE ESTATESAMPLEVILLE VIC 3030

1301011221012102012221332120133322113

*L000001*

X,XXX,XXX.XX

SAMPLE ONLY SAMPLE ONLY

SAMPLE O

NLY

For

per

sona

l use

onl

y

Page 39: For personal use only - ASX · 2011-03-11 · Advanced Molecular Diagnostic Systems 1 1 Dalmore Drive, Scoresby, Victoria 3179 AUSTRALIA T: +61 (0)3 9763‐1287 F: +61 (0)3 9763‐2817

1277

54_0

12JZ

G

The directors reserve the right to make amendments to this form where appropriate.

Lodgement of AcceptanceIf you are applying for Shares and your payment is being made using BPAY®, you do not need to return the slip below. Your payment must be received by no later than 5:00pm (AEDT) on 29 March 2011. Applicants should be aware that their own financial institution may implement earlier cut off times with regards to electronic payment, and should therefore take this into consideration when making payment. It is the responsibility of the applicant to ensure that funds submitted through BPAY are received by this time.

If you are paying by cheque, money order or bank draft, the slip below must be received by Computershare Investor Services Pty Limited (CIS) Melbourne by no later than 5:00pm (AEDT) on 29 March 2011. You should allow sufficient time for this to occur. A reply paid envelope is enclosed for securityholders in Australia. New Zealand holders will need to affix the appropriate postage. Return the slip below with cheque attached.

Neither CIS nor the Company accepts any responsibility if you lodge the slip below at any other address or by any other means.

Privacy StatementPersonal information is collected on this form by CIS, as registrar for securities issuers (“the issuer”), for the purpose of maintaining registers of securityholders, facilitating distribution payments and other corporate actions and communications. Your personal information may be disclosed to our related bodies corporate, to external service companies such as print or mail service providers, or as otherwise required or permitted by law. If you would like details of your personal information held by CIS, or you would like to correct information that is inaccurate, incorrect or out of date, please contact CIS. In accordance with the Corporations Act 2001, you may be sent material (including marketing material) approved by the issuer in addition to general corporate communications. You may elect not to receive marketing material by contacting CIS. You can contact CIS using the details provided on the front of this form or e-mail [email protected]

If you have any enquiries concerning this form or your Entitlement, please contact CIS on 1300 055 821.This form may not be used to notify your change of address. For information, please contact CIS on 1300 850 505 or www.computershare.com (Issuer Sponsored Holders only).

CHESS holders must contact their Controlling Participant to notify a change of address.

Details of your Entitlement based on your Shareholding at 7:00pm (AEDT) on 8 March 2011 are shown in box A on the front of this Entitlement Form.

Rights Shares Applied forYou can apply to accept either all or part of your Entitlement. Enter in Section B the number of Rights Shares you wish to accept from your Entitlement.

Top Up Shares Applied forIf you have applied for your full Entitlement of Rights Shares and wish to apply for Top Up Shares, enter the number of Top Up Shares you wish to apply for in Section C. No Eligible Shareholder is assured of receiving all or any of the Top Up Shares applied for.

Acceptance MoniesEnter the total amount of acceptance monies payable. To calculate this amount, multiply the total number of Rights Shares applied for in Section B, and if, applicable, the number of Top Up Shares applied for in Section C, by A$0.33.For example, if a Shareholder had a full Entitlement of 100,000 Rights Shares and wished to apply for that Entitlement and 50,000 Top Up Shares, the amount they would write in Section D would be: (100,000 + 50,000) x $0.33 = $49,500Please ensure you complete Section D on the bottom of the form if you have completed Sections B and, if applicable, C.

Payment DetailsYou can apply for shares by utilising the payment options detailed below. Please note that funds are unable to be directly debited from your bank account.

A

B

C

D

E

By making your payment using either electronic means or by cheque, money order or bank draft, you confirm that you agree to all of the terms and conditions as detailed in the Prospectus dated 28 February 2011. 1. If paying with BPAY:

Your BPAY payment must be the amount you have calculated in Section D. Pay using your internet banking facility, using the Biller Code and payment Reference number as printed on the attached Payment Slip.If paying with BPAY you do not need to detach and return the Payment Slip; you may retain it for reference.

2. If paying by cheque, money order or bank draft:Your cheque, money order or bank draft must be for the amount you have calculated in Section D.Your cheque, money order or bank draft must be made in Australian currency and drawn on an Australian branch of a financial institution. Such payment must be made payable to “Genera Biosystems Rights Issue Account” and crossed “Not Negotiable”. Payments not properly drawn may be rejected.Cheques will be processed on the day of receipt and as such, sufficient cleared funds must be held in your account as cheques returned unpaid may not be re-presented and may result in your Acceptance form being rejected. Paperclip (do not staple) your cheque(s) to the Payment Slip where indicated and return both to the address shown below. Cash will not be accepted. Receipt of payment will not be forwarded.

Contact DetailsEnter the name of a contact person and telephone number. These details will only be used in the event that the registry has a query regarding the slip below.

F

GB

I2

NR

B

How to complete the Entitlement and Acceptance FormPlease note that photocopies of this form will not be accepted. These instructions are cross-referenced to each section of the Entitlement and Acceptance Form overleaf.

PAYMENT OPTIONS:1. PAY WITH BPAY OR

Genera Biosystems LimitedC/o Computershare InvestorServices Pty LimitedGPO Box 505Melbourne, Victoria 3001AUSTRALIA

2. PAY BY CHEQUE, MONEY ORDER OR BANK DRAFT.

DETACH AND RETURN THIS PAYMENT SLIP, WITH CHEQUE ATTACHED, TO:

Biller Code:Ref No:

Telephone & Internet Banking – BPAY

Call your bank, credit union or building society to make this payment from your cheque or savings account. More info: www.bpay.com.au

SAMPLE CUSTOMERSAMPLE STREETSAMPLE STREETSAMPLE STREETSAMPLE STREETSAMPLETOWN TAS 7000

Entitlement Number: <xxxxxxxxxx>

123456 1234 5678 9012 3456 78 *I1234567890*

SAMPLE ONLY SAMPLE ONLY

SAMPLE O

NLY

For

per

sona

l use

onl

y